Akan Oton is a member of Barings Alternative Investments, a global real estate, private equity and real assets platform. Akan is a part of the Private Equity / Real Assets team and is responsible for sourcing and underwriting Pharmaceutical investments. Akan has worked in the industry since 2002. Prior to joining the firm in 2017, Akan worked at Sandoz (a division of Novartis) where, among other duties, he was an Executive Director with responsibility for product acquisition, licensing and leading M&A initiatives in generics and specialty brand segments. Prior to Sandoz, Akan worked at Catalent Pharma Solutions where he was responsible for product partnering and technology licensing for the company’s venture group. Akan previously held marketing leadership roles at both Cardinal Health and Johnson & Johnson. Akan holds a B.S. in Mechanical Engineering from Columbia University, a M.S. in Mechanical Engineering from Massachusetts Institute of Technology, where he was a National Science Foundation Graduate Fellow, and an M.B.A. from The Wharton School at the University of Pennsylvania.